# RETRACTION: miR‐25‐3p Reverses Epithelial‐Mesenchymal Transition via Targeting Sema4C in Cisplatin‐Resistance Cervical Cancer Cells

## TL;DR

This retracted study claimed that miR-25-3p reverses drug resistance in cervical cancer by targeting Sema4C, but the findings are unreliable due to duplicated images.

## Contribution

The paper originally proposed a novel mechanism involving miR-25-3p and Sema4C in cervical cancer drug resistance.

## Key findings

- miR-25-3p reverses epithelial-mesenchymal transition in cervical cancer cells.
- Sema4C is identified as a target of miR-25-3p in cisplatin-resistant cells.
- The study suggests a potential therapeutic role for miR-25-3p in cervical cancer treatment.

## Abstract

RETRACTION: J. Song and Y. Li, “miR‐25‐3p Reverses Epithelial‐Mesenchymal Transition via Targeting Sema4C in Cisplatin‐Resistance Cervical Cancer Cells,” Cancer Science 108, no. 1 (2017): 23–31, https://doi.org/10.1111/cas.13104.

The above article, published online on 01 December 2016 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor‐in‐Chief, Masanori Hatakeyama; the Japanese Cancer Association; and John Wiley & Sons Australia Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed inappropriate duplication of image panels (Figures 1b, 2a, b and 3c) between this and several other articles published previously or in the same year by a different group of authors, in a different scientific context. Given the extent of the identified issues, the editors have lost confidence in the data presented and the article's conclusions can no longer be considered reliable. The authors and their institute have been informed of the concerns and the decision to retract but they remained unresponsive.